Physician profile
Robert Ferguson
NPI 1336646496
$1,652.91
in general payments reported to CMS, 2019-2025
16 companies · $438 in 2025
The $438 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $14.18 · 2022: $346 · 2023: $401 · 2024: $454 · 2025: $438.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,103 · Travel and Lodging: $189.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,103.35 |
| Travel and Lodging | $189.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $311.34 | 2022-2025 | |
| Intuitive Surgical, INC. | $189.31 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $185.12 | 2021-2025 | Caplyta |
| Novo Nordisk INC | $174.10 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Exact Sciences Corporation | $135.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $129.43 | 2024-2025 | Airsupra, Breztri |
| Amgen INC. | $116.41 | 2022-2025 | Evenity, Prolia |
| Lilly USA, LLC | $114.90 | 2022-2025 | Mounjaro, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $105.89 | 2022-2023 | |
| Shield Therapeutics INC | $58.01 | 2023-2024 | Accrufer |
| Biohaven Pharmaceutical Holding Company LTD. | $49.32 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $26.66 | 2024 | |
| Neurocrine Biosciences, INC. | $16.07 | 2024 | Ingrezza |
| Pfizer INC. | $14.05 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.60 | 2024 | Voquezna |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $13.36 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Ferguson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.